Drugs / KSP-0243
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05831670 | Apr 2023 → Oct 2024 | ulcerative colitis | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSP-0243 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05831670 ↗ |
| Route | Oral | “Oral administration” NCT05831670 ↗ |